Suppr超能文献

核仁蛋白通过与 EBNA1 mRNA 的 G-四联体结合直接介导 Epstein-Barr 病毒的免疫逃逸。

Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.

机构信息

Institut National de la Santé et de la Recherche Médicale UMR1078; Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 22 avenue Camille Desmoulins, Brest F-29200, France.

Cibles Thérapeutiques, Institut National de la Santé et de la Recherche Médicale UMR1162, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis, 27 rue Juliette Dodu, Paris F-75010, France.

出版信息

Nat Commun. 2017 Jul 7;8:16043. doi: 10.1038/ncomms16043.

Abstract

The oncogenic Epstein-Barr virus (EBV) evades the immune system but has an Achilles heel: its genome maintenance protein EBNA1, which is essential for viral genome maintenance but highly antigenic. EBV has seemingly evolved a system in which the mRNA sequence encoding the glycine-alanine repeats (GAr) of the EBNA1 protein limits its expression to the minimal level necessary for function while minimizing immune recognition. Here, we identify nucleolin (NCL) as a host factor required for this process via a direct interaction with G-quadruplexes formed in GAr-encoding mRNA sequence. Overexpression of NCL enhances GAr-based inhibition of EBNA1 protein expression, whereas its downregulation relieves the suppression of both expression and antigen presentation. Moreover, the G-quadruplex ligand PhenDC3 prevents NCL binding to EBNA1 mRNA and reverses GAr-mediated repression of EBNA1 expression and antigen presentation. Hence the NCL-EBNA1 mRNA interaction is a relevant therapeutic target to trigger an immune response against EBV-carrying cancers.

摘要

致癌性 EBV(Epstein-Barr virus)逃避免疫系统,但有一个致命弱点:其基因组维持蛋白 EBNA1,它对病毒基因组维持至关重要,但高度抗原性。 EBV 似乎进化出了一种系统,其中编码 EBNA1 蛋白甘氨酸-丙氨酸重复序列(GAr)的 mRNA 序列将其表达限制在功能所需的最低水平,同时最大限度地减少免疫识别。在这里,我们通过与 GAr 编码 mRNA 序列中形成的 G-四联体的直接相互作用,确定核仁素(NCL)是该过程所必需的宿主因子。NCL 的过表达增强了基于 GAr 的 EBNA1 蛋白表达抑制,而其下调则解除了对表达和抗原呈递的抑制。此外,G-四联体配体 PhenDC3 可防止 NCL 与 EBNA1 mRNA 结合,并逆转 GAr 介导的 EBNA1 表达和抗原呈递抑制。因此,NCL-EBNA1 mRNA 相互作用是触发针对携带 EBV 癌症的免疫反应的一个相关治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ced/5504353/79bf35d0d479/ncomms16043-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验